Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals Ltd witnessed a remarkable surge on 2 Feb 2026, hitting its upper circuit limit with a 19.99% gain to close at ₹42.13. The stock demonstrated strong buying momentum, outpacing its sector and broader market indices, driven by heightened investor interest and significant unfilled demand.

Biofil Chemicals & Pharmaceuticals Ltd witnessed a remarkable surge on 1 Feb 2026, hitting its upper circuit limit of 20% to close at ₹35.11. This sharp rally was driven by intense buying interest, resulting in the stock outperforming its sector and broader market indices amid a backdrop of subdued investor participation and regulatory trading restrictions.

Biofil Chemicals & Pharmaceuticals Ltd has touched a new 52-week low of Rs.28.79, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance factors.

Biofil Chemicals & Pharmaceuticals Ltd has reached a new 52-week low of Rs.28.9, marking a significant decline in its stock price amid broader market pressures and company-specific performance factors.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Biofil Chemicals & Pharmaceuticals Ltd has reached a new 52-week low of Rs.29.52, marking a significant decline amid broader market pressures and company-specific performance issues. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its financial health and market positioning.

Biofil Chemicals & Pharmaceuticals Ltd has touched a new 52-week low of Rs.30 today, marking a significant decline amid broader market pressures and sectoral underperformance. The stock’s recent trajectory reflects a continuation of downward momentum, with multiple factors contributing to its current valuation.

Biofil Chemicals & Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.31.55 on 12 Jan 2026, marking a significant milestone in its recent price trajectory amid broader market fluctuations and company-specific performance factors.

Biofil Chemicals & Pharmaceuticals Ltd has reached a new 52-week low of Rs.32.21, marking a significant decline in its stock price amid continued underperformance relative to its sector and benchmark indices.

Biofil Chemicals & Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.32.5 on 29 Dec 2025, marking a significant drop amid broader market fluctuations and company-specific performance concerns.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO. This rating was last updated on 06 Oct 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 25 December 2025, providing investors with the latest comprehensive view of the company’s position.

Biofil Chemicals & Pharmaceuticals has reached a new 52-week low of Rs.32.59, marking a significant decline in its stock price amid a period of sustained downward movement. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Biofil Chemicals has experienced a revision in its market evaluation, reflecting shifts in its fundamental and technical outlook. The changes come amid ongoing challenges in profitability and stock performance within the Pharmaceuticals & Biotechnology sector.

Biofil Chemicals & Pharmaceuticals has reached a new 52-week low of Rs.32.6, marking a significant decline in its stock price amid broader market movements and company-specific factors.

Biofil Chemicals & Pharmaceuticals touched a new 52-week low of Rs.35.6 today, marking a significant decline amid a series of consecutive trading sessions with negative returns. The stock has been under pressure, trading below all major moving averages and lagging behind its sector and benchmark indices.

Biofil Chemicals & Pharmaceuticals has reached a new 52-week low of Rs.37.71, marking a significant decline in its stock price amid a period of sustained downward movement. The stock has underperformed its sector and broader market indices, reflecting ongoing challenges in its financial performance and market positioning.

Biofil Chemicals & Pharmaceuticals Ltd. reported a dramatic quarter-on-quarter revenue surge of 110.58% in Q2 FY26, with net sales reaching ₹13.54 crores compared to ₹6.43 crores in Q1 FY26. However, the seemingly positive headline numbers concealed a troubling deterioration in profitability, with net profit collapsing 96.68% to just ₹0.08 crores from ₹2.41 crores in the previous quarter. The stock, trading at ₹39.00 with a market capitalisation of ₹64.00 crores, has declined 38.56% over the past year, significantly underperforming both the Sensex and its pharmaceutical sector peers.